Efficacy and Toxicity of Three Different Concurrent Chemoradiotherapy in Local Advanced Cervical Cancer

OBJECTIVE To observe the efficacy and toxicity of three concurrent chemotherapy regimens in the radiotherapy of local advanced cervical cancer. METHODS The 105 patients with FIGO stage IIB-IIIB cervical cancer were treated with concurrent chemoradiotherapy, and all cases were randomly divided into three groups, DDP group(35 cases) received cisplatin weekly for 4-5 cycles, FP group(35 cases) received fluorouracil and cisplatin combined chemotherapy every 3 weeks for 2 cycles, TP group(35 cases) received paclitaxel and cisplatin combined chemotherapy every 3 weeks for 2 cycles. Then compared acute adverse reaction and the efficacy of all patients. RESULTS The complete remission rates of the three groups were 88.6%, 82.9%, 82.9%, the partial remission rates were 11.4%, 17.1%, 11.4% at one month after radiotherapy, the complete remission rates were 97.1%, 97.1%, 94.3% at three months after radiotherapy, there was no significant difference(P>0.05). The 2-year overall survival rates were 97.1%, 85.7%, 91.4%, the 2-year disease-free survival rates was 82.9%, 85.7%, 88.6%, there was no significant difference. The main acute adverse reactions were bone marrow suppression and gastrointestinal reactions. Grade 3-4 leucopenia and neutropenia incidence was more common in paclitaxel and cisplatin group, Grade 3-4 nausea, vomiting, diarrhea and intestinal obstruction were more common in fluorouracil and cisplatin group (P<0.05). The main long-term adverse reactions were radiation enteritis and radiation cystitis, and the incidence of the three groups had no significant difference. CONCLUSION The short-term efficacy of the three concurrent chemotherapy for the treatment of advanced cervical cancer are similar. The 2-year overall survival rate and disease-free survival rate between three groups is similar. The paclitaxel and cisplatin group arise more severe bone marrow suppression. The fluorouracil and cisplatin group arise more severe gastrointestinal reactions.